Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

"" Company Results for March 2021 Quarter 

Here are the latest quarterly results of the stocks in the . For more detailed updates, check the latest stock quotes.

Click on title to sort Mar 2020 Mar 2021 YoY %-Change   Get More Info
 Name
asc
 Net Sales 
(Rs m) 		 PAT 
(Rs m) 		 Net Sales 
(Rs m) 		 PAT 
(Rs m) 		 Net Sales 
(%) 		 PAT 
(%) 		 P/E* 
(x) 
AUROBINDO PHARMA 61,584 8,825 60,015 8,096 -2.5% -8.3% 15.3  More Info 
AUROBINDO PHARMA 61,584 8,825 60,015 8,096 -2.5% -8.3% 15.3  More Info 
AUROBINDO PHARMA 61,584 8,825 60,015 8,096 -2.5% -8.3% 15.3  More Info 
AUROBINDO PHARMA 61,584 8,825 60,015 8,096 -2.5% -8.3% 15.3  More Info 
BIOCON 15,575 1,675 18,421 3,661 18.3% 118.6% 29.4  More Info 
BIOCON 15,575 1,675 18,421 3,661 18.3% 118.6% 29.4  More Info 
CIPLA 43,762 2,423 46,065 4,155 5.3% 71.5% 15.2  More Info 
CIPLA 43,762 2,423 46,065 4,155 5.3% 71.5% 15.2  More Info 
CIPLA 43,762 2,423 46,065 4,155 5.3% 71.5% 15.2  More Info 
DIVIS LABORATORIES 13,897 3,882 17,882 5,020 28.7% 29.3% 53.8  More Info 
DIVIS LABORATORIES 13,897 3,882 17,882 5,020 28.7% 29.3% 53.8  More Info 
GLENMARK PHARMA 27,675 2,203 28,599 2,339 3.3% 6.2% N.A.  More Info 
LUPIN 38,457 3,903 37,831 4,642 -1.6% 18.9% 18.4  More Info 
LUPIN 38,457 3,903 37,831 4,642 -1.6% 18.9% 18.4  More Info 
LUPIN 38,457 3,903 37,831 4,642 -1.6% 18.9% 18.4  More Info 
PIRAMAL ENTERPRISES 33,410 -25,557 34,016 -6,163 1.8% N.A. N.A.  More Info 
SUN PHARMA 81,849 4,944 85,230 8,480 4.1% 71.5% 13.0  More Info 
SUN PHARMA 81,849 4,944 85,230 8,480 4.1% 71.5% 13.0  More Info 
ZYDUS LIFESCIENCES 37,521 4,135 36,703 7,535 -2.2% 82.2% 11.4  More Info 
ZYDUS LIFESCIENCES 37,521 4,135 36,703 7,535 -2.2% 82.2% 11.4  More Info 
Sector Aggregate 851,765 60,195 870,832 104,342 2.2% 73.3%  

* Trailing 12 months earnings, excluding extraordinary / exceptional items.

Dec 2020 Results  |  Jun 2021 Results  |  Latest Quarter Results  |  View All Results


ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.